Download - Non cirrhotic portal fibrosis
![Page 1: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/1.jpg)
Non Cirrhotic Portal Fibrosis
Dr. Pratik Edwards
![Page 2: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/2.jpg)
![Page 3: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/3.jpg)
Anatomy and Physiology• The portal vein is formed by the union of the superior mesenteric
vein and the splenic vein just posterior to the head of the pancreas at about the level of the second lumbar vertebra
• Enters the liver at the porta hepatis in two main branches, one to each lobe; it is without valves in its larger channels
• Portal blood flow is about 1000–1200ml/min
• Contributes 40ml/min or 72% of the total oxygen supply to the liver• Normal Portal pressure is about 7 – 10 mmHg
• Normal portal vein diameter is 1 cm
![Page 4: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/4.jpg)
Non-cirrhotic portal fibrosis • Syndrome of obscure etiology
• ‘Obliterative portovenopathy’ leading to PHT,
• Massive splenomegaly
• well-tolerated episodes of variceal bleeding • In young adults,
• Low socioeconomic backgrounds
• Normal hepatic functions
![Page 5: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/5.jpg)
Lesion in NCPF
•It is generally vascular.
•Location of lesion: 1. Branches of Portal vein 2. Perisinusoidal area of Liver
![Page 6: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/6.jpg)
Epidemlology• Reported worlwide, but maximum cases from india
• Male predominance of 2:1 to 4:1
• Age: Mainly a disease of young men (25 – 35 years)
• Low socioeconomic background
![Page 7: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/7.jpg)
Etiology
• Poorly understood
• Several Hypothesis are proposed: 1.Malntrition2.Exposure to toxics and metals 3.Recuurent intestinal infections`
![Page 8: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/8.jpg)
1. Infective hypothesisAbdominal Infection
Portal pyaemia
Pylephlebitis
Thrombosis
Sclerosis
Obliteration of small and medium sized portal radicle
![Page 9: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/9.jpg)
2. Exposure to trace metals and chemicalsChronic exporure to :
Arsenic, 8 vinyl chloride monomer, Coppersulfate Methotrexate hypervitaminosis A 6-mercaptopurine azathiopine corticosteroids
![Page 10: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/10.jpg)
3. Immumological and Immunogenetic hypoothesis
• Reduction in cytotoxic/ suppressor T - Lymphocytes
• Decreased T4/T8 lymphocyte ratio
• Reduction in cell mediated immunity
![Page 11: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/11.jpg)
![Page 12: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/12.jpg)
Pathology
• Liver may be normal or markedly nodular.• Nodularity is confined to sub - capsular zone.• Portal venous system shows prominent and dilated branches
with marked sclerosis the wall.• Significant perivascular fibrosis along the portal vein and its
branches.
Gross pathology
![Page 13: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/13.jpg)
Pathology
• Patchy and segmental sub endothelial thickening of the large and medium sized intrahepatic branches of portal vein.
• Emergence of new aberrant portal channels is characteristic of NCPF
Microscopy:
![Page 14: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/14.jpg)
Clinical features
• Gastrointestinal bleed (one or more well tolerated episodes).
• Feeling of lump in left upper quadrant of abdomen (due to enlargement of spleen).
• Left upper quadrant pain (due to perislenitis and splenic infarction)
Symptoms
![Page 15: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/15.jpg)
Clinical features
• Splenomegaly(Size of spleen ranges from 4 – 15cms below left coastal margin)
• Liver enlargement (Palpable upto 2cms below coastal margin)
• Rarely – Jaundice, Ascites and Liver failure.
Signs
![Page 16: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/16.jpg)
Laboratory features• Anaemia (either microcytic hypochromic/
normocytic normochromic)
• Leukopenia
• Thrombocytopenia
• Bone marrow is hypercellular
• Mild compensated DIC(due to endotoxaemia or portosystemic collaterals)
• LFT – normal/ mildly deranged.
![Page 17: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/17.jpg)
Radiology
• Portal and splenic veins are dilated and multiple collateral present at the splenic hilum.
• There is marked thickening of portal vein wall specially of intraheptic branches.
• There may be spontaneous lieno renal shunt.
Ultrasonography
![Page 18: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/18.jpg)
Radiology
• Dilatation of portal and splenic vein along with various collaterals.
Spleno porto venography
Endoscopy
Esophagogastric varices
Anorectal varices
![Page 19: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/19.jpg)
Differential diagnosis:
1. EHPVO (Extra hepatic portal vein obstruction)
2. Compensated cirrhosis in the young
3. Tropical splenomegaly syndrome
4. Splenomegaly of myeloid syndrome
5. Kala azar
6. Felty’s syndrome
![Page 20: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/20.jpg)
![Page 21: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/21.jpg)
ManagementIt involves control of acute bleeding (variceal bleeding) and prevention of rebleeding by medical and surgical means.
Medical management:
1. Emergency treatment
2. Primary Prophylaxis
![Page 22: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/22.jpg)
1. Emergency Mangement• Initial resuscitation with replacement of blood volume loss is
done with blood transfusion and IV fluids • Specific traement of bleeding lesion done by:
a. Pharmacotherapy
b. Endoscopictherapy
c. Ballon tamponade
![Page 23: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/23.jpg)
a. Pharmacotherapy : Drugs used are Somatostatin,
octreotide terlipressin vasopressin : 0.1 – 0.5 u/min
b. Endoscopic therapy : i. Endoscopic variceal ligation: Banding device attached to the tip of the
endoscope is used to ligate varix using rubber bands. One to three bands are applied to each varix
ii. Endoscopic sclerotherapy: sclerosants used are 1.5% sodium tetradecyl
sulphate, cyanoacrylate, 5% ethanolamine oleate, absolute alcohol, 3% phenol in water and
5% phenol in oil
c. Balloon tamponade: Used only in massive bleeding as temporary measure.
![Page 24: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/24.jpg)
2. Primary ProphylaxisUsed in patients with increased chances of bleeding such as patients with large varices, red wale markings on varices and severe liver failure.
It includes:
a. b– blockers
b. Vasodilators
c. Combined therapy
![Page 25: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/25.jpg)
a. b – Blockers: Noncardioselective b blockers like propanolol and nadolol are used.
These drugs act by reducing portal and collateral blood flow.
Doses : - Propranolol : 20 mg every 12 hours until there is 25% reduction in resting heart rate Nadolol: 10 mg every 12 hours
b. Vasodilators: Isosorbide mononitrate reduce portal pressure gradient.
c. Combined therapy: Both b – blockers and Isosrbide mononitrate are used.
![Page 26: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/26.jpg)
Surgical ManagementIndication for Surgery:
1. Failure of endoscopic therapy to control acute bleeding.
2. Recurrent bleeding.
3. Symptomatic hypersplenism.
4. Repeated splenic infection.
5. Patient who desires for one time treatment.
![Page 27: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/27.jpg)
Surgery options are: 1. Porto – systemic shunt:
a. Total shunt: Portal blood is completely diverted to systemic circulation.
Eg: -Central splenorenal shunt with splenectomy, -Mesocaval shunt, -Portocaval shunt.
b. Selective shunts: Decompresses the gastrosplenic- portal zone with maintained portal perfusion of the liver through hepato petal collateral.
Eg:- -Distal spleno renal shunt (Warren shunt), -Distal spleno caval shunt, -Gastroepiploic to left renal shunt, -Left gastric vein to left renal vein shunt.
![Page 28: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/28.jpg)
2. Devascularisation procedure:
Indications: -failed shunt, -patient who have no shuntable vein -in emergency when shunt can not be performed.
Eg: Sugiura deevascularization
![Page 29: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/29.jpg)
• The prognosis of patients with NCPF is good
• 5 years survival in patients in whom variceal bleeding can be controlled has been reported to be approximately 95–100%.
• It is not merely absence of cirrhosis, but also of hepatic venous outflow obstruction, such as veno-occlusive disease and Budd–Chiari syndrome.
![Page 30: Non cirrhotic portal fibrosis](https://reader034.vdocuments.site/reader034/viewer/2022042516/55cdd87fbb61eb89518b4858/html5/thumbnails/30.jpg)
THANK YOU